Spotlight
About
News
CME/CE
Subscribe
Partnerships
Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
If approved, relugolix, estradiol, and norethindrone acetate tablets (Myfembree; Myovant Sciences, Pfizer) could be game-changing for pain management in women with moderate-to-severe endometriosis pain.
Articles in this issue
Delayed diagnosis of a bowel injury at laparoscopy
In this issue: Adnexal torsion, abnormal uterine bleeding, and endometriosis awareness month
Understanding abnormal uterine bleeding in adolescents
Adnexal torsion requires careful diagnosis, management
Bringing awareness to endometriosis
Celebrating Laura E. Riley, MD
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Recent Videos
Related Content
